EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Alogliptin-Pioglitazone and Insulin Regimen for Inpatient Glycemic Control: A Randomized Continuous Glucose Monitoring Pilot Trial

Parson Camuto, Dioze Guadagnini, Heloisa B Assalin, Daniela O Magro, Andrey Santos, Mario Ja Saad

AACE Endocrinology and Diabetes · 2026-09 · 13 (5) · 762-769

DOI: 10.1016/j.aed.2026.06.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AACE Endocrinology and Diabetes, 2026-09. Verfasst von Parson Camuto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FAPESP, CNPq.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Hospitalized patients with type 2 diabetes (T2D) frequently develop hyperglycemia, hypoglycemia, and glycemic variability, which are associated with adverse outcomes outside the intensive care unit. This pilot randomized controlled trial evaluated whether adding a fixed-dose combination (FDC) of alogliptin/pioglitazone to standard basal-bolus insulin improved time in range (TIR), reduced hypoglycemia and/or bolus insulin requirements versus placebo, while generating effect size estimates for a future multicenter trial.

Methods

In this randomized, double-blind, placebo-controlled pilot study, the placebo group (n = 12) received basal-bolus insulin (neutral protamine Hagedorn plus regular insulin) with placebo, whereas the intervention group (IG) (n = 18) received the same insulin regimen plus daily alogliptin/pioglitazone FDC (25/15 mg). Continuous glucose monitoring (FreeStyle Libre 2) assessed TIR (70-180 mg/dL) as the primary endpoint, together with time above range and time below range, during a prespecified 4-d postrandomisation analysis period.

Results

The IG achieved significantly higher TIR than placebo (72.44% vs 38.58%; P 250 mg/dL (2.94% vs 28.16%; P 0.05). By day 4, the IG required significantly lower daily bolus insulin doses (P = 0.0003).

Conclusions

In this highly selected inpatient population, adjunctive alogliptin/pioglitazone added to basal-bolus insulin improved continuous glucose monitoring-derived glycaemic stability. Larger adequately powered multicentre trials are needed to confirm safety and efficacy.

Schlagwörter

Stichwörter der Autor:innen

alogliptinbasal-bolus insulincontinuous glucose monitoringinpatient hyperglycaemiapioglitazonetype 2 diabetes

Autor:innen und Institutionen

  • Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil.

Förderung

  • FAPESP
  • CNPq

Zitieren

APA

Camuto, P., Guadagnini, D., Assalin, H. B., Magro, D. O., Santos, A., & Saad, M. J. (2026). Alogliptin-Pioglitazone and Insulin Regimen for Inpatient Glycemic Control: A Randomized Continuous Glucose Monitoring Pilot Trial. AACE Endocrinology and Diabetes, 13(5), 762-769. https://doi.org/10.1016/j.aed.2026.06.010

Vancouver

Camuto P, Guadagnini D, Assalin HB, Magro DO, Santos A, Saad MJ. Alogliptin-Pioglitazone and Insulin Regimen for Inpatient Glycemic Control: A Randomized Continuous Glucose Monitoring Pilot Trial. AACE Endocrinology and Diabetes. 2026;13(5):762-769. doi:10.1016/j.aed.2026.06.010

BibTeX
@article{Camuto2026,
  author = {Camuto, Parson and Guadagnini, Dioze and Assalin, Heloisa B and Magro, Daniela O and Santos, Andrey and Saad, Mario Ja},
  title = {Alogliptin-Pioglitazone and Insulin Regimen for Inpatient Glycemic Control: A Randomized Continuous Glucose Monitoring Pilot Trial},
  journal = {AACE Endocrinology and Diabetes},
  year = {2026},
  volume = {13},
  number = {5},
  pages = {762--769},
  doi = {10.1016/j.aed.2026.06.010}
}
Kostenlos starten →